Related Experiment Video

Updated: May 22, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed

Dalton Wamalwa1, Sarah Benki-Nugent, Agnes Langat

  • 1Department of Paediatrics, University of Nairobi, Nairobi, Kenya. dalton@africaonline.co.ke

The Pediatric Infectious Disease Journal
|May 1, 2012
PubMed

Insights

Late diagnosis of Human Immunodeficiency Virus type 1 (HIV-1) is common in African infants. Early diagnosis and treatment are critical for improving survival rates in these young children.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Late presentation of Human Immunodeficiency Virus type 1 (HIV-1) infection is a significant challenge in African infants.
  • Understanding mortality predictors is crucial for timely intervention.

Purpose of the Study:

  • To determine the incidence and correlates of mortality in infants diagnosed with HIV-1 by five months of age.
  • To identify factors associated with increased mortality risk in this vulnerable population.

Main Methods:

  • A cohort of 99 infants diagnosed with HIV-1 by five months of age was studied.
  • Survival rates and mortality predictors were analyzed.

Main Results:

  • The twelve-month survival rate was 66.8%.
  • Factors predicting mortality included advanced World Health Organization stage (3 or 4), underweight, wasting, microcephaly, low hemoglobin, pneumonia, and gastroenteritis.

Conclusions:

  • Early Human Immunodeficiency Virus type 1 (HIV-1) diagnosis and initiation of antiretroviral therapy before symptom onset are essential for improving infant survival.
  • Identifying and addressing risk factors can enhance clinical management and outcomes.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...